Boehringer Ingelheim initiates three Phase III clinical trials aimed at precision oncology in cancer types with limited treatment options, according to company materials shared by multiple outlets. The studies include DAREON®-Lung-1 and DAREON®-NEC-1, which evaluate obrixtamig, an “IgG-like” bispecific T-cell engager designed to target DLL3. These trials use a biomarker-informed approach intended to help identify eligible patients and guide treatment decisions. DAREON®-Lung-1 focuses on small cell lung cancer (SCLC), while DAREON®-NEC-1 targets extrapulmonary neuroendocrine carcinoma (epNEC). A third study, Beamion LUNG-3, investigates zongertinib in a lung cancer setting. The announcements frame the program as part of Boehringer Ingelheim’s effort to advance targeted therapies for aggressive cancers where existing options are limited. The sources do not provide additional trial endpoints, locations, or enrollment figures in the text provided.